Estimation of pharmacokinetic parameters with the R package PK.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 284, doi. 10.1002/pst.449
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2011 AND VI 10 AND IP 3
Results: 16
1
2
Detecting data fabrication in clinical trials from cluster analysis perspective.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 257, doi. 10.1002/pst.462
- By:
- Publication type:
- Article
3
Literature Review July-September 2010.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 280, doi. 10.1002/pst.473
- By:
- Publication type:
- Article
4
The role of the minimum clinically important difference and its impact on designing a trial.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 250, doi. 10.1002/pst.459
- By:
- Publication type:
- Article
5
Bayesian biostatistics and diagnostic medicine broemeling Lyle D (2007) ISBN 1584887672; 216 pages; £ 42.99, $ 83.95 Chapman & Hall/CRC;.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 283, doi. 10.1002/pst.385
- By:
- Publication type:
- Article
6
Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 218, doi. 10.1002/pst.450
- By:
- Publication type:
- Article
7
Intent-to-treat analysis in the presence of off-treatment or missing data.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 191, doi. 10.1002/pst.421
- By:
- Publication type:
- Article
8
On assessing the presence of evaluation-time bias in progression-free survival in randomized trials.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 213, doi. 10.1002/pst.443
- By:
- Publication type:
- Article
9
An MSE-reduced estimator for the response proportion in a two-stage clinical trial.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 277, doi. 10.1002/pst.414
- By:
- Publication type:
- Article
10
Review of the statistical analysis of the dog telemetry study.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 236, doi. 10.1002/pst.454
- By:
- Publication type:
- Article
11
Issues for stratified randomization based on a factor derived from a continuous baseline variable.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 232, doi. 10.1002/pst.453
- By:
- Publication type:
- Article
12
Estimation of the limit of detection for quantal response bioassays.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 203, doi. 10.1002/pst.435
- By:
- Publication type:
- Article
13
Statistical thinking for non-statisticians in drug regulation Richard Kay (2007) ISBN 0470319712; 296 pages; £39.95, €52.90, $80.00 Wiley;.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 282, doi. 10.1002/pst.372
- By:
- Publication type:
- Article
14
Large sample inference for an assay quality measure used in high-throughput screening.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 227, doi. 10.1002/pst.452
- By:
- Publication type:
- Article
15
Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 265, doi. 10.1002/pst.463
- By:
- Publication type:
- Article
16
Another view on the analysis of cardiovascular morbidity/mortality trials.
- Published in:
- Pharmaceutical Statistics, 2011, v. 10, n. 3, p. 196, doi. 10.1002/pst.434
- By:
- Publication type:
- Article